vs
HAEMONETICS CORP（HAE）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
HAEMONETICS CORP的季度营收约是Orthofix Medical Inc.的1.6倍（$346.4M vs $219.9M），HAEMONETICS CORP净利率更高（28.1% vs -1.0%，领先29.1%），HAEMONETICS CORP同比增速更快（4.8% vs 2.0%），HAEMONETICS CORP自由现金流更多（$209.9M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 1.5%）
豪洛捷（Haemonetics）是全球血液与血浆供应及服务提供商，于20世纪70年代由艾伦·（杰克）·莱瑟姆博士在马萨诸塞州内蒂克创立，业务围绕血液相关产品及配套服务展开，为全球医疗领域提供血液管理相关的专业解决方案。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
HAE vs OFIX — 直观对比
营收规模更大
HAE
是对方的1.6倍
$219.9M
营收增速更快
HAE
高出2.8%
2.0%
净利率更高
HAE
高出29.1%
-1.0%
自由现金流更多
HAE
多$193.1M
$16.8M
两年增速更快
OFIX
近两年复合增速
1.5%
损益表 — Q4 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $346.4M | $219.9M |
| 净利润 | $97.3M | $-2.2M |
| 毛利率 | 57.2% | 71.1% |
| 营业利润率 | 36.1% | 0.2% |
| 净利率 | 28.1% | -1.0% |
| 营收同比 | 4.8% | 2.0% |
| 净利润同比 | — | 92.4% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HAEOFIX
| Q1 26 | $346.4M | — | ||
| Q4 25 | $339.0M | $219.9M | ||
| Q3 25 | $327.3M | $205.6M | ||
| Q2 25 | $321.4M | $203.1M | ||
| Q1 25 | $330.6M | $193.6M | ||
| Q4 24 | $348.5M | $215.7M | ||
| Q3 24 | $345.5M | $196.6M | ||
| Q2 24 | $336.2M | $198.6M |
净利润HAEOFIX
| Q1 26 | $97.3M | — | ||
| Q4 25 | $44.7M | $-2.2M | ||
| Q3 25 | $38.7M | $-22.8M | ||
| Q2 25 | $34.0M | $-14.1M | ||
| Q1 25 | $58.0M | $-53.1M | ||
| Q4 24 | $37.5M | $-29.1M | ||
| Q3 24 | $33.8M | $-27.4M | ||
| Q2 24 | $38.4M | $-33.4M |
毛利率HAEOFIX
| Q1 26 | 57.2% | — | ||
| Q4 25 | 59.7% | 71.1% | ||
| Q3 25 | 59.5% | 72.2% | ||
| Q2 25 | 59.8% | 68.7% | ||
| Q1 25 | 58.4% | 62.8% | ||
| Q4 24 | 55.5% | 69.0% | ||
| Q3 24 | 54.2% | 68.7% | ||
| Q2 24 | 52.0% | 67.8% |
营业利润率HAEOFIX
| Q1 26 | 36.1% | — | ||
| Q4 25 | 19.9% | 0.2% | ||
| Q3 25 | 17.9% | -8.3% | ||
| Q2 25 | 16.8% | -7.9% | ||
| Q1 25 | 21.6% | -25.2% | ||
| Q4 24 | 16.9% | -5.3% | ||
| Q3 24 | 15.0% | -9.6% | ||
| Q2 24 | 11.8% | -12.5% |
净利率HAEOFIX
| Q1 26 | 28.1% | — | ||
| Q4 25 | 13.2% | -1.0% | ||
| Q3 25 | 11.8% | -11.1% | ||
| Q2 25 | 10.6% | -6.9% | ||
| Q1 25 | 17.5% | -27.4% | ||
| Q4 24 | 10.8% | -13.5% | ||
| Q3 24 | 9.8% | -13.9% | ||
| Q2 24 | 11.4% | -16.8% |
每股收益（稀释后）HAEOFIX
| Q1 26 | — | — | ||
| Q4 25 | $0.95 | $-0.05 | ||
| Q3 25 | $0.81 | $-0.57 | ||
| Q2 25 | $0.70 | $-0.36 | ||
| Q1 25 | $1.17 | $-1.35 | ||
| Q4 24 | $0.74 | $-0.76 | ||
| Q3 24 | $0.66 | $-0.71 | ||
| Q2 24 | $0.74 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $245.4M | $82.0M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $796.3M | $450.0M |
| 总资产 | $2.4B | $850.6M |
| 负债/权益比越低杠杆越低 | 1.53× | — |
8季度趋势，按日历期对齐
现金及短期投资HAEOFIX
| Q1 26 | $245.4M | — | ||
| Q4 25 | $363.4M | $82.0M | ||
| Q3 25 | $296.4M | $62.9M | ||
| Q2 25 | $292.9M | $65.6M | ||
| Q1 25 | $306.8M | $58.0M | ||
| Q4 24 | $320.8M | $83.2M | ||
| Q3 24 | $299.3M | $30.1M | ||
| Q2 24 | $344.4M | $26.4M |
总债务HAEOFIX
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $157.2M | ||
| Q2 25 | $1.2B | $157.0M | ||
| Q1 25 | $1.2B | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
股东权益HAEOFIX
| Q1 26 | $796.3M | — | ||
| Q4 25 | $911.5M | $450.0M | ||
| Q3 25 | $849.2M | $442.5M | ||
| Q2 25 | $882.3M | $458.3M | ||
| Q1 25 | $820.8M | $458.3M | ||
| Q4 24 | $906.9M | $503.1M | ||
| Q3 24 | $878.9M | $525.9M | ||
| Q2 24 | $905.4M | $546.0M |
总资产HAEOFIX
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.5B | $850.6M | ||
| Q3 25 | $2.4B | $832.6M | ||
| Q2 25 | $2.5B | $837.2M | ||
| Q1 25 | $2.5B | $823.1M | ||
| Q4 24 | $2.5B | $893.3M | ||
| Q3 24 | $2.5B | $867.9M | ||
| Q2 24 | $2.5B | $882.0M |
负债/权益比HAEOFIX
| Q1 26 | 1.53× | — | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | 0.36× | ||
| Q2 25 | 1.39× | 0.34× | ||
| Q1 25 | 1.49× | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $293.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $209.9M | $16.8M |
| 自由现金流率自由现金流/营收 | 60.6% | 7.6% |
| 资本支出强度资本支出/营收 | 9.5% | 4.9% |
| 现金转化率经营现金流/净利润 | 3.01× | — |
| 过去12个月自由现金流最近4个季度 | $417.1M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流HAEOFIX
| Q1 26 | $293.2M | — | ||
| Q4 25 | $93.6M | $27.7M | ||
| Q3 25 | $111.3M | $12.4M | ||
| Q2 25 | $17.4M | $11.6M | ||
| Q1 25 | $116.6M | $-18.4M | ||
| Q4 24 | $43.8M | $23.7M | ||
| Q3 24 | $48.8M | $11.7M | ||
| Q2 24 | $-27.4M | $9.0M |
自由现金流HAEOFIX
| Q1 26 | $209.9M | — | ||
| Q4 25 | $87.2M | $16.8M | ||
| Q3 25 | $106.3M | $2.5M | ||
| Q2 25 | $13.6M | $4.5M | ||
| Q1 25 | $100.9M | $-25.1M | ||
| Q4 24 | $35.2M | $15.2M | ||
| Q3 24 | $39.4M | $6.3M | ||
| Q2 24 | $-33.1M | $-360.0K |
自由现金流率HAEOFIX
| Q1 26 | 60.6% | — | ||
| Q4 25 | 25.7% | 7.6% | ||
| Q3 25 | 32.5% | 1.2% | ||
| Q2 25 | 4.2% | 2.2% | ||
| Q1 25 | 30.5% | -13.0% | ||
| Q4 24 | 10.1% | 7.0% | ||
| Q3 24 | 11.4% | 3.2% | ||
| Q2 24 | -9.8% | -0.2% |
资本支出强度HAEOFIX
| Q1 26 | 9.5% | — | ||
| Q4 25 | 1.9% | 4.9% | ||
| Q3 25 | 1.5% | 4.8% | ||
| Q2 25 | 1.2% | 3.5% | ||
| Q1 25 | 4.7% | 3.5% | ||
| Q4 24 | 2.5% | 4.0% | ||
| Q3 24 | 2.7% | 2.7% | ||
| Q2 24 | 1.7% | 4.7% |
现金转化率HAEOFIX
| Q1 26 | 3.01× | — | ||
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
